blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3496753

EP3496753 - PD-1 ANTIBODY FORMULATION [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  20.10.2023
Database last updated on 13.07.2024
FormerGrant of patent is intended
Status updated on  06.07.2023
FormerExamination is in progress
Status updated on  10.02.2022
FormerRequest for examination was made
Status updated on  17.05.2019
FormerThe international publication has been made
Status updated on  17.02.2018
Most recent event   Tooltip12.07.2024Lapse of the patent in a contracting state
New state(s): DK, SM		published on 14.08.2024 [2024/33]
Applicant(s)For all designated states
Innovent Biologics (Suzhou) Co., Ltd.
168 Dongping Street
Suzhou Industrial Park
Suzhou, Jiangsu 215123 / CN
[2019/25]
Inventor(s)01 / CAO, Wei
168 Dongping Street
Suzhou Industrial Park
Suzhou Jiangsu 215123 / CN
02 / LI, Junfeng
168 Dongping Street
Suzhou Industrial Park
Suzhou Jiangsu 215123 / CN
03 / LIU, Xiaolin
168 Dongping Street
Suzhou Industrial Park
Suzhou Jiangsu 215123 / CN
 [2019/25]
Representative(s)Regimbeau
20, rue de Chazelles
75847 Paris Cedex 17 / FR
[2019/25]
Application number, filing date17838513.417.07.2017
[2019/25]
WO2017CN93141
Priority number, dateWO2016CN9409409.08.2016         Original published format: PCT/CN2016/094094
[2019/25]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018028383
Date:15.02.2018
Language:EN
[2018/07]
Type: A1 Application with search report 
No.:EP3496753
Date:19.06.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 15.02.2018 takes the place of the publication of the European patent application.
[2019/25]
Type: B1 Patent specification 
No.:EP3496753
Date:22.11.2023
Language:EN
[2023/47]
Search report(s)International search report - published on:CN15.02.2018
(Supplementary) European search report - dispatched on:EP28.02.2020
ClassificationIPC:A61K39/395, C07K16/28, A61P35/00
[2023/28]
CPC:
C07K16/2818 (EP,US); A61K39/39591 (EP); A61K47/26 (US);
A61P35/00 (EP); C07K2317/94 (EP)
Former IPC [2019/25]A61K39/395
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/25]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:PD-1-ANTIKÖRPERFORMULIERUNG[2019/25]
English:PD-1 ANTIBODY FORMULATION[2019/25]
French:FORMULATION D'ANTICORPS ANTI-PD-1[2019/25]
Entry into regional phase07.02.2019National basic fee paid 
07.02.2019Search fee paid 
07.02.2019Designation fee(s) paid 
07.02.2019Examination fee paid 
Examination procedure07.02.2019Examination requested  [2019/25]
09.09.2020Amendment by applicant (claims and/or description)
09.02.2022Despatch of a communication from the examining division (Time limit: M04)
31.05.2022Reply to a communication from the examining division
07.07.2023Communication of intention to grant the patent
11.10.2023Fee for grant paid
11.10.2023Fee for publishing/printing paid
11.10.2023Receipt of the translation of the claim(s)
Fees paidRenewal fee
07.02.2019Renewal fee patent year 03
01.07.2020Renewal fee patent year 04
19.06.2021Renewal fee patent year 05
31.05.2022Renewal fee patent year 06
07.06.2023Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT22.11.2023
DK22.11.2023
HR22.11.2023
LT22.11.2023
LV22.11.2023
NL22.11.2023
PL22.11.2023
RS22.11.2023
SE22.11.2023
SM22.11.2023
BG22.02.2024
NO22.02.2024
GR23.02.2024
IS22.03.2024
PT22.03.2024
[2024/33]
Former [2024/26]AT22.11.2023
HR22.11.2023
LT22.11.2023
LV22.11.2023
NL22.11.2023
PL22.11.2023
RS22.11.2023
SE22.11.2023
BG22.02.2024
NO22.02.2024
GR23.02.2024
IS22.03.2024
PT22.03.2024
Former [2024/25]AT22.11.2023
HR22.11.2023
LT22.11.2023
NL22.11.2023
PL22.11.2023
RS22.11.2023
SE22.11.2023
BG22.02.2024
NO22.02.2024
GR23.02.2024
IS22.03.2024
PT22.03.2024
Former [2024/24]AT22.11.2023
HR22.11.2023
LT22.11.2023
NL22.11.2023
RS22.11.2023
SE22.11.2023
BG22.02.2024
NO22.02.2024
GR23.02.2024
IS22.03.2024
PT22.03.2024
Former [2024/23]AT22.11.2023
LT22.11.2023
NL22.11.2023
BG22.02.2024
GR23.02.2024
IS22.03.2024
PT22.03.2024
Former [2024/21]LT22.11.2023
NL22.11.2023
BG22.02.2024
GR23.02.2024
IS22.03.2024
Former [2024/20]GR23.02.2024
IS22.03.2024
Documents cited:Search[I]  - WANG W ET AL, "ANTIBODY STRUCTURE, INSTABILITY, AND FORMULATION", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, US, (20070101), vol. 96, no. 1, doi:10.1002/JPS.20727, ISSN 0022-3549, pages 1 - 26, XP009084505 [I] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1002/jps.20727
International search[A]WO2004056875  (WYETH CORP [US], et al) [A] 1-14 * the whole document *;
 [A]WO2006121168  (ONO PHARMACEUTICAL CO [JP], et al) [A] 1-14;
 [Y]WO2011110604  (UCB PHARMA SA [BE], et al) [Y] 1-14 * claims 7-9, 14, description, page 21, lines 27-34, page 22, lines 20-31, page 23, lines 22-34 *;
 [Y]WO2011110621  (UCB PHARMA SA [BE], et al) [Y] 1-14 * description, page 22, lines 15-18, page 23, line 33-page 24, line 5 *;
 [Y]WO2012135408  (MERCK SHARP & DOHME [US], et al) [Y] 1-14 * claims 16-23, 25-26, 28-30 *;
 [Y]WO2016011357  (ADVAXIS INC [US], et al) [Y] 1-14 * claim 36 *;
 [Y]WO2016032927  (PFIZER [US], et al) [Y] 1-14 * claims 13-14 *;
 [A]WO2016092419  (RINAT NEUROSCIENCE CORP [US]) [A] 1-14 * the whole document *;
 [A]  - DAUGHERTY, A.L. et al., "Formulation and delivery issues for monoclonal antibody therapeutics", Advanced Drug Delivery Reviews., (20060522), vol. 58, pages 686 - 706, XP024892149 [A] 1-14

DOI:   http://dx.doi.org/10.1016/j.addr.2006.03.011
by applicantWO2004056875
 WO2006121168
 WO2011110604
 WO2011110621
 WO2012135408
 WO2016011357
 WO2016032927
 WO2016092419
 WO2017024465
    - DAUGHERTY et al., Advanced Drug Delivery Reviews, (20060522), vol. 58, pages 686 - 706
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.